Collegium Pharmaceutical, Inc. $COLL Shares Bought by Sei Investments Co.

Sei Investments Co. grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 191.6% in the first quarter, Holdings Channel reports. The institutional investor owned 130,620 shares of the specialty pharmaceutical company’s stock after buying an additional 85,830 shares during the period. Sei Investments Co.’s holdings in Collegium Pharmaceutical were worth $4,320,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. State of Wyoming lifted its holdings in Collegium Pharmaceutical by 75.5% in the first quarter. State of Wyoming now owns 9,214 shares of the specialty pharmaceutical company’s stock valued at $305,000 after acquiring an additional 3,965 shares during the period. NewEdge Wealth LLC increased its holdings in Collegium Pharmaceutical by 59.6% during the 1st quarter. NewEdge Wealth LLC now owns 38,893 shares of the specialty pharmaceutical company’s stock valued at $1,286,000 after acquiring an additional 14,529 shares in the last quarter. PNC Financial Services Group Inc. raised its position in Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 418 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Collegium Pharmaceutical by 0.3% during the first quarter. Dimensional Fund Advisors LP now owns 833,192 shares of the specialty pharmaceutical company’s stock worth $27,551,000 after acquiring an additional 2,712 shares during the last quarter. Finally, Jennison Associates LLC purchased a new stake in shares of Collegium Pharmaceutical in the first quarter valued at about $676,000.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on COLL shares. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 25th. Finally, Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Collegium Pharmaceutical Stock Up 0.0%

Shares of NASDAQ COLL opened at $35.73 on Thursday. The firm has a market cap of $1.16 billion, a P/E ratio of 17.52 and a beta of 0.73. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. Collegium Pharmaceutical, Inc. has a 1 year low of $29.70 and a 1 year high of $50.79. The firm’s 50 day moving average price is $34.95 and its 200 day moving average price is $37.24.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same period in the previous year, the firm posted $1.49 EPS. Collegium Pharmaceutical’s revenue was up 8.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.